Colchicine in acutely decompensated heart failure: the COLICA trial.

ABSTRACT:

Background and aims

Acute heart failure (AHF) promotes inflammatory activation, which is associated with worse outcomes. Colchicine has proven effective in other cardiovascular conditions characterized by inflammatory activation, but has never been evaluated in the setting of AHF.

Methods

This multicenter, randomized, double-blind, and placebo-controlled trial included patients with AHF, requiring ≥40 mg of intravenous furosemide, regardless of their left ventricular ejection fraction (LVEF) and inpatient or outpatient setting. Patients were randomized within the first 24 h of presentation to receive either colchicine or placebo, with loading dose of 2 mg, followed by 0.5 mg every 12 h for 8 weeks.

Results

A total of 278 patients [median age 75 years, LVEF 40%, baseli

SUBMITTER: Pascual-Figal D 

PROVIDER: S-EPMC11637759 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature